Pre-made Tenatumomab benchmark antibody ( Whole mAb Radiolabelled, anti-TNC therapeutic antibody, Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-561

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-561 Category Tag

Product Details

Pre-Made Tenatumomab biosimilar, Whole mAb Radiolabelled, Anti-TNC Antibody: Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tenatumomab is a monoclonal antibody designed for the treatment of cancer.

Products Name (INN Index)

Pre-Made Tenatumomab biosimilar, Whole mAb Radiolabelled, Anti-TNC Antibody: Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C therapeutic antibody

INN Name

Tenatumomab

Target

TNC

Format

Whole mAb Radiolabelled

Derivation

Mouse

Species Reactivity

Human

CH1 Isotype

IgG2b

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2007

Companies

sigma-tau SpA

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Cancer

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

TNC

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide